Share on StockTwits

NxStage Medical (NASDAQ:NXTM) President Joseph E. Turk, Jr. unloaded 1,500 shares of NxStage Medical stock on the open market in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $14.00, for a total value of $21,000.00. Following the completion of the sale, the president now directly owns 129,447 shares in the company, valued at approximately $1,812,258. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

NxStage Medical (NASDAQ:NXTM) traded down 0.71% on Monday, hitting $13.96. The stock had a trading volume of 214,224 shares. NxStage Medical has a 1-year low of $8.77 and a 1-year high of $15.00. The stock’s 50-day moving average is $12.69 and its 200-day moving average is $12.25. The company’s market cap is $857.4 million.

NxStage Medical (NASDAQ:NXTM) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.09) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.11) by $0.02. The company had revenue of $72.20 million for the quarter, compared to the consensus estimate of $69.44 million. During the same quarter last year, the company posted ($0.08) earnings per share. NxStage Medical’s revenue was up 17.2% compared to the same quarter last year. On average, analysts predict that NxStage Medical will post $-0.40 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on NXTM shares. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of NxStage Medical in a research note on Friday, May 9th. They now have a $19.00 price target on the stock, down previously from $21.00. Analysts at Wells Fargo & Co. downgraded shares of NxStage Medical from a “market perform” rating to an “underperform” rating in a research note on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $16.83.

NxStage Medical, Inc (NASDAQ:NXTM) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.